File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation

TitleTreatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation
Authors
KeywordsInduction-concurrent chemotherapy
Nasopharyngeal cancer
Accelerated radiotherapy
Issue Date2005
Citation
International Journal of Radiation Oncology - Biology - Physics, 2005, v. 63, n. 5, p. 1331-1338 How to Cite?
AbstractPurpose: To explore a more effective strategy for treating nasopharyngeal carcinoma with extensive locoregional disease. Methods and Materials: Between October 1998 and January 2003, 49 patients with Stage IV(A-B) disease infiltrating or abutting neurologic structures were treated with induction-concurrent chemotherapy and accelerated radiotherapy (RT). A combination of cisplatin and 5-fluorouracil was used in the induction phase and single-agent cisplatin in the concurrent phase. All patients were irradiated with conformal techniques at 2 Gy/fraction, six daily fractions weekly, to a total dose of 70 Gy. Results: Although 92% of patients had one or more acute toxicities Grade 3 or worse, 96% completed the whole course of RT, and 92% had five or more cycles of chemotherapy. The great majority of toxicities were uneventful, but 1 patient died of neutropenic sepsis. With a median follow-up of 3.1 years, 20 patients had failure at one or more sites and 15 patients died. The 3-year locoregional and distant failure-free rate was 77% and 75%, respectively, and the overall survival rate was 71%. At last follow-up, 27% of patients had developed late Grade 3 or worse toxicity (24% were hearing impairments), but none had radiation-induced neurologic damage. Conclusion: The current strategy achieved encouraging results for this poor prognostic group, and confirmation of the therapeutic gain by a prospective randomized trial is warranted. © 2005 Elsevier Inc.
Persistent Identifierhttp://hdl.handle.net/10722/213898
ISSN
2015 Impact Factor: 4.495
2015 SCImago Journal Rankings: 2.274

 

DC FieldValueLanguage
dc.contributor.authorLee, Anne W M-
dc.contributor.authorYau, T. K.-
dc.contributor.authorWong, Dominique H M-
dc.contributor.authorChan, Elian W K-
dc.contributor.authorYeung, Rebecca M W-
dc.contributor.authorNg, W. T.-
dc.contributor.authorTong, Macy-
dc.contributor.authorSoong, Inda S.-
dc.contributor.authorSze, W. M.-
dc.date.accessioned2015-08-19T13:41:08Z-
dc.date.available2015-08-19T13:41:08Z-
dc.date.issued2005-
dc.identifier.citationInternational Journal of Radiation Oncology - Biology - Physics, 2005, v. 63, n. 5, p. 1331-1338-
dc.identifier.issn0360-3016-
dc.identifier.urihttp://hdl.handle.net/10722/213898-
dc.description.abstractPurpose: To explore a more effective strategy for treating nasopharyngeal carcinoma with extensive locoregional disease. Methods and Materials: Between October 1998 and January 2003, 49 patients with Stage IV(A-B) disease infiltrating or abutting neurologic structures were treated with induction-concurrent chemotherapy and accelerated radiotherapy (RT). A combination of cisplatin and 5-fluorouracil was used in the induction phase and single-agent cisplatin in the concurrent phase. All patients were irradiated with conformal techniques at 2 Gy/fraction, six daily fractions weekly, to a total dose of 70 Gy. Results: Although 92% of patients had one or more acute toxicities Grade 3 or worse, 96% completed the whole course of RT, and 92% had five or more cycles of chemotherapy. The great majority of toxicities were uneventful, but 1 patient died of neutropenic sepsis. With a median follow-up of 3.1 years, 20 patients had failure at one or more sites and 15 patients died. The 3-year locoregional and distant failure-free rate was 77% and 75%, respectively, and the overall survival rate was 71%. At last follow-up, 27% of patients had developed late Grade 3 or worse toxicity (24% were hearing impairments), but none had radiation-induced neurologic damage. Conclusion: The current strategy achieved encouraging results for this poor prognostic group, and confirmation of the therapeutic gain by a prospective randomized trial is warranted. © 2005 Elsevier Inc.-
dc.languageeng-
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physics-
dc.subjectInduction-concurrent chemotherapy-
dc.subjectNasopharyngeal cancer-
dc.subjectAccelerated radiotherapy-
dc.titleTreatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ijrobp.2005.05.061-
dc.identifier.pmid16169677-
dc.identifier.scopuseid_2-s2.0-27344455265-
dc.identifier.hkuros266086-
dc.identifier.volume63-
dc.identifier.issue5-
dc.identifier.spage1331-
dc.identifier.epage1338-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats